N
TRDA icon

Natixis’s Entrada Therapeutics TRDA Stock Holding History

Natixis’s Portfolio TRDA Stock Details TRDA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-31,186
Closed -$433K – 1156
2024
Q1 		$433K Hold
31,186
– – ﹤0.01% 652
2023
Q4 		$517K Hold
31,186
– – ﹤0.01% 608
2023
Q3 		$505K Hold
31,186
– – ﹤0.01% 604
2023
Q2 		$468K Hold
31,186
– – ﹤0.01% 649
2023
Q1 		$444K Buy
31,186
+5,000
+19% +$66.8K ﹤0.01% 639
2022
Q4 		$354K Buy
+26,186
New +$459K ﹤0.01% 757

Other funds holding TRDA

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
MAM
MPM Asset Management Boston, Massachusetts $44.5M AUM 47.28% 1-Year Est. Return
5VM
5AM Venture Management San Francisco, California $360M AUM 345.76% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
SG
StepStone Group La Jolla, California $207M AUM 12.33% 1-Year Est. Return